Patritumab

Patritumab deruxtecan showed significant PFS improvement in EGFR-mutated NSCLC patients post-TKI treatment, outperforming standard platinum-based doublet chemotherapy in the HERTHENA-Lung02 trial. Daiichi Sankyo and Merck plan to discuss these findings with regulatory authorities.

Daiichi Sankyo and MSD report Phase III HERTHENA-Lung02 trial of patritumab deruxtecan met primary endpoint of progression-free survival in EGFR-mutated NSCLC patients. The trial showed a significant PFS improvement for patritumab deruxtecan versus chemotherapy, with a safety profile consistent with previous studies.

Merck and Daiichi Sankyo's patritumab deruxtecan met primary endpoint in Phase III HERTHENA-Lung02 study for EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival. Safety profile consistent with prior studies, though two grade 5 interstitial lung disease deaths occurred. Full results to be presented at a medical meeting.

Patritumab deruxtecan showed significant PFS improvement in HERTHENA-Lung02 trial for EGFR-mutated NSCLC patients previously treated with EGFR TKI, compared to platinum plus pemetrexed chemotherapy.

Daiichi Sankyo and Merck's patritumab deruxtecan shows significant PFS improvement in EGFR-mutated NSCLC post-EGFR TKI treatment, prompting discussions with global regulatory authorities.

Daiichi Sankyo and Merck's antibody-drug conjugate, patritumab deruxtecan, met Phase 3 trial goals, delaying EGFR-mutated non-small cell lung cancer progression better than chemotherapy. The drug uses an antibody to target tumor cells and release a toxic chemical. Daiichi has six ADCs using deruxtecan chemotherapy, including Enhertu, with sales of $1.8 billion in H1 2024. Merck's $22 billion deal with Daiichi aims to bolster its pipeline as Keytruda patents near expiration.

Dr. Barbara Pistilli presents encouraging phase II ICARUS-BREAST01 results for patritumab deruxtecan, a new antibody-drug conjugate for metastatic breast cancer, showing a 53.5% response rate and 9.4 months median progression-free survival. The study identifies factors influencing response, suggesting potential as a new therapy for advanced hormone-dependent breast cancer.

DESTINY-Breast12 study highlights T-DXd's efficacy in HER2+ mBC patients with brain metastases, showing a 12-month PFS rate of 61.6% and varying ORR based on BM status. Tucatinib remains preferred for active BMs, but T-DXd demonstrates promising CNS activity. Safety profile aligns with previous reports, with ILD/pneumonitis as a key risk. T-DXd supports treatment for HER2+ mBC, including stable and active BMs.

FDA issues Complete Response Letter for Daiichi Sankyo and Merck's patritumab deruxtecan BLA due to inspection findings at a third-party manufacturer, without issues identified with efficacy or safety data. Patritumab deruxtecan is a potential first-in-class HER3-directed ADC, jointly developed by Daiichi Sankyo and Merck, aiming to treat EGFR-mutated NSCLC patients previously treated with two or more systemic therapies.